Phase 1 trial of dasatinib plus erlotinib in adults with recurrent malignant glioma

To determine the maximum tolerated dose (MTD) and dose-limiting toxicity (DLT) of dasatinib, an inhibitor of the Src family kinase proteins, with erlotinib, an epidermal growth factor receptor tyrosine kinase inhibitor, among recurrent malignant glioma patients. Once daily dasatinib was escalated in...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Reardon, David A., Vredenburgh, James J., Desjardins, Annick, Peters, Katherine B., Sathornsumetee, Sith, Threatt, Stevie, Sampson, John H., Herndon, James E., Coan, April, McSherry, Frances, Rich, Jeremy N., McLendon, Roger E., Zhang, Steven, Friedman, Henry S.
Formato: Artigo
Idioma:Inglês
Publicado em: 2012
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3690584/
https://ncbi.nlm.nih.gov/pubmed/22407177
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s11060-012-0848-x
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados